Burden and management of severe asthma in Russia: results from international observational study
- 作者: Aisanov Z.1, Kurbacheva O.2, Emelyanov A.3, Ignatova G.4, Teichman L.5, Makarova J.5, Fedosenko S.6, Alfonso R.5, Elfishawy T.5
-
隶属关系:
- Pirogov Russian National Research Medical University
- National Research Center “Institute of Immunology”
- Mechnikov North-Western State Medical University
- South Ural State Medical University
- GSK
- Siberian State Medical University
- 期: 卷 96, 编号 3 (2024)
- 页面: 212-217
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/255125
- DOI: https://doi.org/10.26442/00403660.2024.03.202625
- ID: 255125
如何引用文章
全文:
详细
Aim. To assess clinical and demographic characteristics of severe asthma (SA) patients and their management in Russian Federation.
Materials and methods. This publication provides data for Russian part of population of the international observational study. In Phase I, retrospective analysis of medical records of patients with SA was performed with assessment of clinical and demographic data, medical history, comorbidities, treatment approaches and healthcare utilization. Phase II was a cross-sectional collection of patient-reported outcomes: level of asthma control assessed by ACT (Asthma Control Test) and health-related quality of life (HRQoL) measured using the EQ-5D-5L questionnaire. Phase I patients were enrolled into Phase II if they signed a written consent form.
Results. A total of 315 patients were included in Phase I of the study, 106 (33.6%) of them entered Phase II. Majority of study participants were either obese (n=103; 39.8%) or overweight (n=94; 36.3%). The most common comorbidities were cardiovascular diseases (n=217; 71.4%), followed by chronic respiratory diseases (n=198; 68.8%). There were 268 (85.1%) patients who had at least one exacerbation during last 12 months. Data for blood eosinophil count were available in 176 patients; 81.3% of them (n=143) had only one test in the last 12 months. The mean (SD) last available blood eosinophil count was 161.2 (181.2) cells/mm3. Serum Immunoglobulin E (IgE) value was known for 88 patients, and the mean (SD) last measured IgE value was 254.3 (249.7) ng/mL. Only 4.7% of Phase II participants had ACT scores indicative of controlled asthma (>20). As much as 74.5% had scores ≤15 suggesting uncontrolled disease. Most patients also had impaired HRQoL.
Conclusion. Most SA patients had poor disease control with frequent exacerbations and high number of comorbidities. Blood eosinophils and IgE level measurements were not evaluated routinely which might be a barrier for appropriate phenotyping and treatment selection.
作者简介
Zaurbek Aisanov
Pirogov Russian National Research Medical University
Email: yana.j.makarova@gsk.com
ORCID iD: 0000-0002-4044-674X
д-р мед. наук, проф. каф. пульмонологии ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»
俄罗斯联邦, MoscowOksana Kurbacheva
National Research Center “Institute of Immunology”
Email: yana.j.makarova@gsk.com
ORCID iD: 0000-0003-3250-0694
д-р мед. наук, проф., зав. отд. бронхиальной астмы ФГБУ ГНЦ «Институт иммунологии»
俄罗斯联邦, MoscowAlexander Emelyanov
Mechnikov North-Western State Medical University
Email: yana.j.makarova@gsk.com
ORCID iD: 0000-0002-8574-6869
д-р мед. наук, проф., зав. каф. пульмонологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
俄罗斯联邦, Saint PetersburgGalina Ignatova
South Ural State Medical University
Email: yana.j.makarova@gsk.com
ORCID iD: 0000-0002-0877-6554
д-р мед. наук, проф., зав. каф. терапии Института дополнительного профессионального образования ФГБОУ ВО ЮУГМУ
俄罗斯联邦, ChelyabinskLindsey Teichman
GSK
Email: yana.j.makarova@gsk.com
ORCID iD: 0000-0002-2600-9383
биостатистик и эпидемиолог GSK
阿拉伯联合酋长国Janina Makarova
GSK
编辑信件的主要联系方式.
Email: yana.j.makarova@gsk.com
ORCID iD: 0000-0002-1102-7618
канд. мед. наук, рук. медико-экономического направления GSK
俄罗斯联邦Sergey Fedosenko
Siberian State Medical University
Email: yana.j.makarova@gsk.com
ORCID iD: 0000-0001-6655-3300
д-р мед. наук, проф. каф. общей врачебной практики и поликлинической терапии ФГБОУ ВО СибГМУ
俄罗斯联邦, TomskRafael Alfonso
GSK
Email: yana.j.makarova@gsk.com
ORCID iD: 0000-0002-7060-5131
ст. дир. эпидемиологического направления биологических препаратов в респираторной медицине GSK
美国Tamer Elfishawy
GSK
Email: yana.j.makarova@gsk.com
ORCID iD: 0009-0001-4307-569X
региональный рук. терапевтического направления специализированной медицинской помощи GSK
阿拉伯联合酋长国参考
- de Groot JC, Ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1(1):00024-2015. doi: 10.1183/23120541.00024-2015
- Neffen H, Fritscher C, Schacht FC, et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica. 2005;17(3):191-7. doi: 10.1590/s1020-49892005000300007
- Bavbek S, Misirligil Z. A breath for health: An exploratory study in severe asthma patients in Turkey. Allergy. 2008;63:1218-27. doi: 10.1111/j.1398-9995.2008.01706.x
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73. doi: 10.1183/09031936.00202013
- Franco R, Nascimento HF, Cruz AA, et al. The economic impact of severe asthma to low-income families. Allergy. 2009;64(3):478-83. doi: 10.1111/j.1398-9995.2009.01981.x
- Cruz AA, Bousquet PJ. The unbearable cost of severe asthma in underprivileged populations. Allergy. 2009;64(3):319-21. doi: 10.1111/j.1398-9995.2009.02026.x
- Polosa R. An overview of chronic severe asthma. Intern Med J. 2008;38(3):190-8. doi: 10.1111/j.1445-5994.2007.01547.x
- Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315-23. doi: 10.1164/rccm.200906-0896OC
- Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199-204. doi: 10.1164/rccm.200208-789OC
- Архипов В.В., Айсанов З.P., Авдеев C.Н. Эффективность комбинаций ингаляционных глюкокортикостероидов и длительно действующих β-агонистов в условиях реальной медицинской практики: результаты многоцентрового кросс-секционного исследования у российских пациентов с бронхиальной астмой. Пульмонология. 2021;31(5):613-26 [Arkhipov VV, Aisanov ZR, Avdeev SN. Effectiveness of inhaled corticosteroids and long-acting β-agonists combinations in real clinical practice: results of a multicenter cross-sectional study in Russian patients with asthma. Pulmonologiya. 2021;31(5):613-26 (in Russian)]. doi: 10.18093/0869-0189-2021-31-5-613-626
- Melgert BN, Ray A, Hylkema MN, et al. Are there reasons why adult asthma is more common in females? Curr Allergy Asthma Rep. 2007;7(2):143-50. doi: 10.1007/s11882-007-0012-4
- Wang E, Wechsler ME, Tran TN, et al. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020;157(4):790-804. doi: 10.1016/j.chest.2019.10.053
- Белевский А.С., Ненашева Н.М., Кравченко Н.Ю., и др. Данные Общероссийского регистра пациентов с тяжелой бронхиальной астмой. Терапевтический архив. 2022;94(7):865-71 [Belevskiy AS, Nenasheva NM, Kravchenko NYu, et al. Data from the Russian Severe Asthma Registry (RSAR). Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(7):865-71 (in Russian)]. doi: 10.26442/00403660.2022.07.201713
- Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P. Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms. Mediators Inflamm. 2016;2016:3690628. doi: 10.1155/2016/3690628
- Black MH, Anderson A, Bell RA, et al. Prevalence of asthma and its association with glycemic control among youth with diabetes. Pediatrics. 2011;128(4):e839-47. doi: 10.1542/peds.2010-3636
- Tai A, Tran H, Roberts M, et al. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax. 2014;69(9):805-10. doi: 10.1136/thoraxjnl-2013-204815
- Mirabelli MC, Beavers SF, Chatterjee AB, Moorman JE. Age at asthma onset and subsequent asthma outcomes among adults with active asthma. Respir Med. 2013;107(12):1829-36. doi: 10.1016/j.rmed.2013.09.022
- Zein JG, Dweik RA, Comhair SA, et al. Asthma Is More Severe in Older Adults. PLoS One. 2015;10(7):e0133490. doi: 10.1371/journal.pone.0133490
- Szefler SJ, Raphiou I, Zeiger RS, et al. Seasonal variation in asthma exacerbations in the AUSTRI and VESTRI studies. ERJ Open Research. 2019;5:00153-2018. doi: 10.1183/23120541.00153-2018
- Singh AM, Busse WW. Asthma exacerbations. 2: Aetiology. Thorax. 2006;61(9):809-16. doi: 10.1136/thx.2005.045179
- Pellegrino R, Viegi G, Brusasco et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-68. doi: 10.1183/09031936.05.00035205
- Quezada WA, Kwak ES, Reibman J, et al. Predictors of asthma exacerbation among patients with poorly controlled asthma despite inhaled corticosteroid treatment. Ann Allergy Asthma Immunol. 2016;116(2):112. doi: 10.1016/j.anai.2015.11.011
- Demoly P, Gueron B, Annunziata K, et al. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev. 2010;19(116):150-7. doi: 10.1183/09059180.00002110
- de Carvalho-Pinto RM, Cukier A, Angelini L, et al. Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med. 2012;106(1):47-56. doi: 10.1016/j.rmed.2011.08.013
- Tiotiu A. Biomarkers in asthma: state of the art. Asthma Research and Practice. 2018;4(1):10. doi: 10.1186/s40733-018-0047-4
- Hilvering B, Xue L, Pavord ID. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Ther Adv Respir Dis. 2015;9(4):135-45. doi: 10.1177/1753465815581279
- Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-97. doi: 10.1056/NEJMoa1403291
- Nenasheva N, Belevsky A. Characteristics of Patients with Severe Asthma in the Russian Federation – the Russian Severe Asthma Registry. Am J Respir Crit Care Med. 2019;199:A1337. doi: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1337
- Mahboub B. Recommendations for severe asthma management from a Gulf Cooperation Council expert panel aiming to optimize regional clinical practice. Medical Research Archives. 2019;7(12):1-8. doi: 10.18103/mra.v7i12.1999